chHES-8-KO-P53
NERCe003-A-3
General#
Cell Line |
|
| hPSCreg Name | NERCe003-A-3 |
| Alternative name(s) |
chHES-8-KO-P53
|
| Cell line type | Human embryonic stem cell (hESC) |
| Last update | 31st January 2018 |
| User feedback | |
Provider |
|
| Generator | National Engineering and Research Center of Human Stem Cell (NERC) |
| Owner | National Engineering and Research Center of Human Stem Cell (NERC) |
External Databases |
|
| BioSamples | SAMEA994658 |
| Cellosaurus | CVCL_VF84 |
General Information |
|
| Publications | |
| Is the cell line available in principle? |
No |
| Subclone of | |
Donor Information#
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA104132951 |
Ethics#
We are currently revising this section.hESC Derivation#
| Date of derivation | 2017-11-10 |
| Supernumerary embryos from IVF treatment? |
Yes
Separation of research and IVF treatment?
Yes |
| PGD Embryo? |
No |
Culture Conditions#
| Feeder cells |
human embryonic fibroblast |
||||||||||||
| Passage method | Mechanically | ||||||||||||
| O2 Concentration | 5 % | ||||||||||||
| CO2 Concentration | 5 % | ||||||||||||
| Medium |
Other medium:
Base medium: D/F 12
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
|
|||
| TRA 1-81 |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SOX2 |
Yes |
|
Self-renewal
Positive
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Differentiation Potency
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46，XY
|
Other Genotyping (Cell Line) |
|
Genetic Modification#
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.